Cerebral Microembolism in the Critically Ill With Acute Kidney Injury

Clinical Trial Summary

The primary objective of this study is to investigate the impact of continuous renal replacement therapy and intermittent renal replacement therapy on microbubble / cerebral microemboli generation in a cohort of critically ill patients with dialysis-dependent acute kidney injury.

See also
Status	Clinical Trial	Phase
Completed	`NCT02021045` - Cerebral Microembolism During Hemodialysis	N/A
Completed	`NCT03802760` - Cerebral Microembolism in Cardiology
Completed	`NCT02378116` - Left Atrial Appendage Closure During Open Heart Surgery	N/A
Completed	`NCT01028794` - Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke Patients	Phase 1/Phase 2

See also

Status

Clinical Trial

Phase

Completed

NCT02021045 - Cerebral Microembolism During Hemodialysis

N/A

Completed

NCT03802760 - Cerebral Microembolism in Cardiology

Completed

NCT02378116 - Left Atrial Appendage Closure During Open Heart Surgery

N/A

Completed

NCT01028794 - Autologous Bone Marrow Mononuclear Cell Transplantation for Stroke Patients

Phase 1/Phase 2

Interventional studies are often prospective and are specifically tailored to evaluate direct impacts of treatment or preventive measures on disease.

Observational studies are often retrospective and are used to assess potential causation in exposure-outcome relationships and therefore influence preventive methods.

Expanded access is a means by which manufacturers make investigational new drugs available, under certain circumstances, to treat a patient(s) with a serious disease or condition who cannot participate in a controlled clinical trial.

Clinical trials are conducted in a series of steps, called phases - each phase is designed to answer a separate research question.

Phase 1: Researchers test a new drug or treatment in a small group of people for the first time to evaluate its safety, determine a safe dosage range, and identify side effects.
Phase 2: The drug or treatment is given to a larger group of people to see if it is effective and to further evaluate its safety.
Phase 3: The drug or treatment is given to large groups of people to confirm its effectiveness, monitor side effects, compare it to commonly used treatments, and collect information that will allow the drug or treatment to be used safely.
Phase 4: Studies are done after the drug or treatment has been marketed to gather information on the drug's effect in various populations and any side effects associated with long-term use.

NCT number	NCT02621749
Study type	Interventional
Source	University Hospital Inselspital, Berne
Contact
Status	Terminated
Phase	N/A
Start date	January 2017
Completion date	November 6, 2022

Cerebral Microembolism in the Critically Ill With Acute Kidney Injury — COMET-AKI

Clinical Trial Summary

Clinical Trial Description

Study Design

Related Conditions & MeSH terms